Cargando…

Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E–deficient mice

Cyclophilin A (CyPA; encoded by Ppia) is a ubiquitously expressed protein secreted in response to inflammatory stimuli. CyPA stimulates vascular smooth muscle cell migration and proliferation, endothelial cell adhesion molecule expression, and inflammatory cell chemotaxis. Given these activities, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Nigro, Patrizia, Satoh, Kimio, O'Dell, Michael R., Soe, Nwe Nwe, Cui, Zhaoqiang, Mohan, Amy, Abe, Jun-ichi, Alexis, Jeffrey D., Sparks, Janet D., Berk, Bradford C.
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023134/
https://www.ncbi.nlm.nih.gov/pubmed/21173104
http://dx.doi.org/10.1084/jem.20101174
Descripción
Sumario:Cyclophilin A (CyPA; encoded by Ppia) is a ubiquitously expressed protein secreted in response to inflammatory stimuli. CyPA stimulates vascular smooth muscle cell migration and proliferation, endothelial cell adhesion molecule expression, and inflammatory cell chemotaxis. Given these activities, we hypothesized that CyPA would promote atherosclerosis. Apolipoprotein E–deficient (Apoe(−/−)) mice fed a high-cholesterol diet for 16 wk developed more severe atherosclerosis compared with Apoe(−/−)Ppia(−/−) mice. Moreover, CyPA deficiency was associated with decreased low-density lipoprotein uptake, VCAM-1 (vascular cell adhesion molecule 1) expression, apoptosis, and increased eNOS (endothelial nitric oxide synthase) expression. To understand the vascular role of CyPA in atherosclerosis development, bone marrow (BM) cell transplantation was performed. Atherosclerosis was greater in Apoe(−/−) mice compared with Apoe(−/−)Ppia(−/−) mice after reconstitution with CyPA(+/+) BM cells, indicating that vascular-derived CyPA plays a crucial role in the progression of atherosclerosis. These data define a role for CyPA in atherosclerosis and suggest CyPA as a target for cardiovascular therapies.